Bioequivalence and Bioavailability Forum

Hi Lmsmqa,

❝ In a clinical trial study where multiple doses are done…

Do I get you right – a high accumulation ratio leading to low concentrations after a single dose and high ones in steady state? If not, can you elaborate on the design and its purpose?

Cross validation (e.g., Deming regression, Bland–Altman plot) compares two methods in the same concentration range.

If you really want to go that way, you would have to:

• Measure spiked samples by method 2 (high range).
  
• Dilute samples suitable for method 1 (low range).
  Important: Measuring diluted samples has to be validated in method 1.
  
• Measure samples by method 1.
  
• Cross validate based on results obtained by method 2 (divided by the dilution factor) vs. obtained by method 1 (diluted).

Personally I agree with ElMaestro’s gut feeling that – as long as both methods are validated – cross validation might not be necessary.

---

PS: Personally I never came across such a case. In BE studies of widely spread doses (and hence, concentrations) we regularly used different calibration ranges. Was never a regulatory issue to accept the entire submission package.
On the other hand, in dose proportionality studies and SD/MD with high accumulation we always used a method covering the entire range. Was sometimes difficult (limited range of the MS, quenching in fluorescence detection: quadratic model, weighting 1/x², 1/y², or – better – 1/s²_y). I would never use different methods and/or different labs in the same study.